Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. Characterization of WT and TLR5−/− mice (related to Fig. 1).
  • Fig. S2. Pyr-pHEMA nanogels are equivalent in size to PLGA nanoparticle vaccines (related to Fig. 1 and Fig. 5).
  • Fig. S3. Knockout of the TLR5 receptor results in lower germinal center formation in mice immunized with a PLGA nanovaccine (related to Fig. 1).
  • Fig. S4. PLGA nanoparticle trafficking from the injection site to lymphoid tissue on day 6 and accumulation in the liver and kidneys at days 2 and 6 after injection (related to Fig. 2).
  • Fig. S5. Expression of CD86 activation marker (related to Fig. 2).
  • Fig. S6. Injection site analysis (related to Fig. 2).
  • Fig. S7. Cell populations in the spleen and lymph node of immunized antibiotic-fed mice (related to Fig. 4).
  • Fig. S8. Immunological characterization of Pyr-pHEMA nanogels (related to Fig. 5).
  • Fig. S9. Pyr-pHEMA nanogels do not differentially accumulate in tissue after 6 days relative to soluble formulation (related to Fig. 5).
  • Fig. S10. Immunomodulatory effects of Pyr-pHEMA are mediated through TLR2 (related to Fig. 6).

Download PDF

Files in this Data Supplement: